Universe Pharmaceuticals INC completed the acquisition of Best Praise International Limited on June 30, 2026. The company issued 4,376,552 Class A ordinary shares as full consideration for the target's five pharmaceutical patents related to age-related diseases and neurodegenerative conditions. Post-transaction, the issuer has 5,008,313 Class A and 16,077 Class B ordinary shares outstanding. Universe Pharmaceuticals INC operates in the pharmaceutical industry.

Universe Pharmaceuticals INC reported unaudited financial results for the six months ended March 31, 2026. Total revenue decreased slightly to $9,036,190 from $9,152,915 in the prior year period, driven by a 26.2% drop in self-manufactured traditional Chinese medicine sales volume, partially offset by an 81.5% increase in average selling prices for third-party products. The company reported a net loss of $1,554,813 compared to a net loss of $3,284,755 previously. Gross profit improved to $3,342,511 with a 37.0% margin against 34.6% in the prior year. Selling expenses rose significantly to $3,285,367 from $2,276,728, while general and administrative expenses fell sharply to $1,463,798 from $3,117,727. The company holds $27,559,730 in cash and has a dual-class share structure effective since February 13, 2026. Universe Pharmaceuticals INC operates in the pharmaceutical industry, specializing in the development, manufacturing, and sale of traditional Chinese medicine derivatives and third-party healthcare products.

Universe Pharmaceuticals INC entered into a Share Purchase Agreement on June 17, 2026, to acquire 100% of Best Praise International Limited for US$10,751,000, payable through the issuance of 4,376,552 Class A ordinary shares. The target company holds five pharmaceutical patents in China relating to age-related diseases, neurodegenerative conditions, cognitive disorders, and cardiovascular applications. Universe Pharmaceuticals INC operates in the pharmaceutical industry, focusing on drug delivery technologies and pharmaceutical compounds.